Clinical Trial Update: Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) [Phase 2]

View source ↗

Summary

A Phase 2 study of triheptanoin to prevent hypoglycemia in patients with Medium-chain acyl-CoA dehydrogenase deficiency has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medium-chain Acyl-coa Dehydrogenase Deficiency

Drugs mentioned

• Dojolvi (triheptanoin) (triheptanoin)

Snippet

Sponsor: Jerry Vockley, MD, PhD | Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency | Phase 2 | Status: SUSPENDED